Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. de Miguel-Perez D, et al. Among authors: rolfo c. J Exp Clin Cancer Res. 2022 Jun 2;41(1):186. doi: 10.1186/s13046-022-02379-1. J Exp Clin Cancer Res. 2022. PMID: 35650597 Free PMC article.
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M. Reguart N, et al. Among authors: rolfo c. Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2. Lung Cancer. 2014. PMID: 24636848 Clinical Trial.
On the pharmacogenetics of non-small cell lung cancer treatment.
Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E. Santarpia M, et al. Among authors: rolfo c. Expert Opin Drug Metab Toxicol. 2016;12(3):307-17. doi: 10.1517/17425255.2016.1141894. Epub 2016 Feb 17. Expert Opin Drug Metab Toxicol. 2016. PMID: 26761638 Review.
Recent developments in the use of immunotherapy in non-small cell lung cancer.
Santarpia M, Giovannetti E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R. Santarpia M, et al. Among authors: rolfo c. Expert Rev Respir Med. 2016 Jul;10(7):781-98. doi: 10.1080/17476348.2016.1182866. Epub 2016 May 13. Expert Rev Respir Med. 2016. PMID: 27148808 Review.
cMET Exon 14 Skipping: From the Structure to the Clinic.
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. Van Der Steen N, et al. Among authors: rolfo c. J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. Epub 2016 May 17. J Thorac Oncol. 2016. PMID: 27223456 Free article. Review.
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, Archila P, Rodríguez J, Cuello M, Ortíz C, Franco S, Rolfo C, Rosell R, on behalf of the CLICaP. Cardona AF, et al. Among authors: rolfo c. Oncotarget. 2016 Sep 19;7(42):68933-68942. doi: 10.18632/oncotarget.12112. Oncotarget. 2016. PMID: 27926478 Free PMC article.
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C. Porta R, et al. Among authors: rolfo c. Crit Rev Oncol Hematol. 2017 May;113:256-267. doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23. Crit Rev Oncol Hematol. 2017. PMID: 28427515 Review.
391 results